CASE STUDY PRA Exceeds Tough Enrollment Goals Service Delivery Model Drives Positive ResultsPRA Exceeds Tough Enrollment Goals Service Delivery Model Drives Positive Results Primary Endpoint Safety, tolerability, and efficacy of Study Drug PRA Services Full service Indication Hepatitis C Drug Class Caspase inhibitor Study Phase IIb Business Segment Product Registration Regions North America Western Europe Central Europe STUDY DESCRIPTION A Phase IIb, Double-blind, randomized, parallel-group, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Study Drug in adults with chronic hepatitis C virus infection A large biotech client awarded PRA a full-service contract to perform a Phase IIb study of hepatitis C drugs with a target to enroll 240 patients i

Join for free to read